Tradestie Institutional Equity Comparison Engine

DMAC vs XOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 2โ€“8 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while XOMA counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus XOMA at 21.5x Forward P/E and -3.9% operating margin (-22.6% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XOMA
DMAC N/M vs XOMA 21.5x Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -3.9% ยท YoY +0.0% vs -22.6%
Momentum & Technical Winner DMAC
1Y +55.3% vs +44.0% ยท 52W Pos 55% vs 78%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs UNCLASSIFIED (100th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% XOMA +43.98% Spread: +13.59 pp (DMAC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DMAC TTM Op. Margin: 0.0% XOMA TTM Op. Margin: -3.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DMAC vs XOMA. Trailing 12-month operating profitability (DMAC 0.0% vs XOMA -3.9%) and valuation multiples (DMAC N/M vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (2) vs XOMA (8)
Institutional Metric DMAC XOMA Criterion Row Winner
Market Capitalization Scale $503.1M $781.8M Larger Scale XOMA
Trailing P/E Ratio Valuation N/M 28.2x Lower Multiple XOMA
Forward P/E Ratio Valuation N/M 21.5x Lower Multiple XOMA
Revenue Growth (YoY) Growth +0.0% -22.6% Higher Growth DMAC
Operating Margin (TTM) Profitability 0.0% -3.9% Higher Margin DMAC
Net Profit Margin Profitability 0.0% 69.6% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency -114.6% 34.2% Higher ROE XOMA
52-Week Range Position Momentum 55% ($5โ€“$11) 78% ($22โ€“$45) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 0.68ฮฒ ยท 37% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs XOMA Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor XOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.